CancerTherapyAdvisor· @CancerTherAdvsr · X·· 5 天前评分70
正文 · 原文
At #ESMO26, results from the Phase 2 DOVACC trial showed adding the UV1 cancer vaccine to olaparib +/- durvalumab did not significantly improve PFS in BRCA wild-type recurrent ovarian cancer🧬
@myESMO #ESMO2026
Full article: https://bit.ly/3UaDJVt
84 浏览 · 0 赞 · 0 转发 · 0 回复
来源：CancerTherapyAdvisor · x.com